Lv1
36 积分 2023-09-22 加入
Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study
17小时前
已完结
WHO position on HPV vaccines
1天前
已完结
Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
5天前
已完结
Integration of dosimetric parameters, clinical factors, and radiomics to predict symptomatic radiation pneumonitis in lung cancer patients undergoing combined immunotherapy and radiotherapy
1个月前
已完结
A nationwide survey on knowledge, attitude and practice regarding human papillomavirus (HPV), HPV-related disease and HPV vaccine among young adults in China
2个月前
已完结
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
OA02.03 Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcomes in the Phase 3 CheckMate 816 Study
2个月前
已关闭
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial
2个月前
已完结
皖公网安备34019202002308
